Inside the $101 Million Competition Racing to Reverse Aging in Humans
XPRIZE Healthspan pits 10 teams against each other to restore muscle, cognition, and immunity in older adults by 2030.
Summary
XPRIZE Healthspan is a $101 million global competition led by researcher Jamie Justice and entrepreneur Peter Diamandis, designed to identify treatments that genuinely reverse aspects of aging. Ten finalist teams, selected from 40 applicants, must each run yearlong randomized controlled clinical trials testing therapies aimed at restoring muscle strength, cognitive function, and immune health in older adults. Approaches include senolytics — drugs that clear damaged 'zombie' cells — exercise interventions, and personalized biomarker-driven medicine. A grand prize winner will be announced in 2030. Justice, who bridges academia and industry, emphasizes rigorous science in a field notorious for unproven products and 'purely scammy' companies, while also advocating for an open, inclusive research culture that avoids gatekeeping.
Detailed Summary
The longevity field has long struggled with a credibility problem: a booming market of anti-aging products with little rigorous evidence behind them. XPRIZE Healthspan was created specifically to address this gap, offering $101 million to research teams that can demonstrate real, measurable restoration of age-related decline in a structured clinical setting.
Leading the effort is Jamie Justice, a gerontology researcher and executive director of the competition, who left a tenure-track position at Wake Forest University to take on the role alongside entrepreneur Peter Diamandis. Justice represents a science-grounded voice in a field that attracts both serious researchers and fringe theorists alike.
Ten finalist teams, narrowed down from 40 global applicants in 2025, are now required to conduct yearlong randomized controlled clinical trials — the gold standard in medical research. Their therapies target three core domains of aging: muscle function, cognitive performance, and immune resilience. Approaches span senolytics (drugs designed to eliminate senescent 'zombie' cells that accumulate with age), structured exercise protocols, and personalized medicine guided by individual biomarkers.
The competition is significant because it introduces competitive, high-stakes accountability into longevity research. Rather than self-reported outcomes or small observational studies, teams must produce trial-level evidence. Results are expected to converge around a grand prize announcement in 2030, which could meaningfully shift which therapies gain mainstream scientific and clinical traction.
Caveats remain: the article is a profile piece based on a conference presentation, and the full STAT+ content is paywalled, limiting detail on individual team methodologies. Additionally, clinical trial results in aging research are notoriously difficult to standardize due to heterogeneity in older adult populations. Still, the competition's structure — rigorous trials, independent judging, and public accountability — positions it as a potential credibility anchor for the broader longevity field.
Key Findings
- 10 finalist teams must complete yearlong randomized controlled trials testing aging-reversal therapies before 2030.
- Therapies target three measurable aging domains: muscle strength, cognitive function, and immune system performance.
- Senolytic drugs, exercise interventions, and biomarker-personalized medicine are among the leading competitive approaches.
- Justice warns that 'purely scammy' longevity companies are damaging credibility for legitimate anti-aging science.
- XPRIZE structure introduces rare competitive accountability and trial-level evidence standards to longevity research.
Methodology
This is a news profile article from STAT News, a credible science and health journalism outlet. It is based on a live conference interview and presentation, not a peer-reviewed study. The full article is paywalled, limiting access to deeper methodological or data-level detail.
Study Limitations
The article is a profile piece, not a research summary, so no trial data or outcome measures are presented. Full content is behind a paywall, restricting comprehensive analysis. Readers should track published trial results from individual XPRIZE teams directly for evidence-based conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.